Johnson & Johnson (JNJ)

133.15
4.34 3.37
NYSE : Health Technology
Prev Close 128.81
Open 129.12
Day Low/High 127.22 / 134.00
52 Wk Low/High 109.16 / 154.50
Volume 11.50M
Avg Volume 10.28M
Exchange NYSE
Shares Outstanding 2.64B
Market Cap 345.70B
EPS 5.70
P/E Ratio 23.29
Div & Yield 3.80 (2.86%)

Latest News

Jim Cramer: Here's the Science Behind Our Rally

Jim Cramer: Here's the Science Behind Our Rally

While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.

Johnson & Johnson Is Ready to Rally After Reaching a Downside Price Target

Johnson & Johnson Is Ready to Rally After Reaching a Downside Price Target

While the short-term picture of JNJ suggests more risk is possible, the longer-term patterns are constructive.

3 Japanese Stocks Getting a Boost on Potential Coronavirus Treatments

3 Japanese Stocks Getting a Boost on Potential Coronavirus Treatments

Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.

3 Strong Long-Term Buys for Uncertain Times

3 Strong Long-Term Buys for Uncertain Times

These pharmaceutical names have what it takes amid the current crisis and for the long run.

Good Medicine for a Retest? Johnson & Johnson

Good Medicine for a Retest? Johnson & Johnson

A strong S&P for three days makes me leery of what's ahead, but here's an option in JNJ.

Jim Cramer: Here's What Can Be Bought, Sold Right Now

Jim Cramer: Here's What Can Be Bought, Sold Right Now

The Holy Grail right now are the few companies thriving and that will keep going after this is over, but there are others who will rebound and some who will not.

Johnson & Johnson Weathers Storm but Needs to Build a New Base

Johnson & Johnson Weathers Storm but Needs to Build a New Base

The healthcare giant's charts still show some signs of weakness but also indicate it could rally and make a base from a higher level.

This Health Care Dividend King Offers a Remedy for Hopeless Investors

This Health Care Dividend King Offers a Remedy for Hopeless Investors

JNJ should survive a recession and prove in demand in a health crisis.

Jim Cramer: What to Buy and What to Sell Now, Part 2

Jim Cramer: What to Buy and What to Sell Now, Part 2

In the 2nd of a 3-part series, Jim Cramer goes through all 30 Dow stocks to evaluate what is safe to buy and what you should sell or avoid (like the plague).

The Charts of Johnson & Johnson Show What It's Made Of

The Charts of Johnson & Johnson Show What It's Made Of

The company has grown organically and by acquisitions. It has dealt with adversity and bad news.

Jim Cramer: Do You Really Want to Sell Now?

Jim Cramer: Do You Really Want to Sell Now?

The answer to that question depends on several factors, so let's break them down.

Three Strategies for Income Investors

Three Strategies for Income Investors

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

Want to Beef Up on Dividend Stocks? Here Are Some NOBL Opportunities

Want to Beef Up on Dividend Stocks? Here Are Some NOBL Opportunities

The S&P 500 has added these companies to the Dividend Aristocrats class of 2020.

Consider This Dividend Stock Money in the Bank

Consider This Dividend Stock Money in the Bank

People's United Financial is a 4.5%-yielding dividend aristocrat that's on a path to continued expansion.

Market Direction and Trading Volume, Resilient Boeing, Trading Costco

Market Direction and Trading Volume, Resilient Boeing, Trading Costco

Boeing's new estimate for the FAA's signing off on returning the 737 MAX to commercial skies has been pushed out until summer, June or July? Is that really that bad? Perhaps... this is a positive.

The Week Ahead: Davos, Impeachment, PMI and 25 Key Earnings Reports to Watch

The Week Ahead: Davos, Impeachment, PMI and 25 Key Earnings Reports to Watch

Almost 200 companies are slated to report quarterly results, including 43 S&P 500 constituents.

3 Powerhouse Pharma Stock Favorites

3 Powerhouse Pharma Stock Favorites

These healthcare stalwarts look attractive for growth and income.

Johnson & Johnson Finally Shakes Off Its Bad News 'Overhang'

Johnson & Johnson Finally Shakes Off Its Bad News 'Overhang'

It looks like JNJ has its swagger back.

J&J Raised at Morgan Stanley

Jim Cramer: Don't Be an Armageddonist and Live in Fear of a Crash

Jim Cramer: Don't Be an Armageddonist and Live in Fear of a Crash

Having a bad game does not mean you quit forever. It just means it is time to regroup and rethink strategy.

Jim Cramer: Here's Why the Market Hasn't Stopped Rallying

Jim Cramer: Here's Why the Market Hasn't Stopped Rallying

These are the 10 reasons why we keep going up, despite all the bad news.

Novice Trade: Johnson & Johnson

Novice Trade: Johnson & Johnson

I have been using these down days to buy calls and then selling on the pops up the next.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Amazon Is a Trade for Now, The Fed Pipes Down: Market Recon

Amazon Is a Trade for Now, The Fed Pipes Down: Market Recon

Most important is that the Fed felt the need earlier this week to expand it's minimum offering for overnight repo operations, while also increasing the 14 day repos.

Is the Worst Over for Johnson & Johnson?

Is the Worst Over for Johnson & Johnson?

A lot of investing is just waiting until the market hates good companies.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

Earnings Season Round 2 Starts Today

Earnings Season Round 2 Starts Today

The majority of the S&P 500 stocks will report in the next two weeks. Focus on individual stock picking, but keep stops tight.

Energy Stocks Are Getting Hammered

Energy Stocks Are Getting Hammered

There are myriad concerns across the energy complex, the most prevalent one centered around declining global growth reducing the demand for energy.